[{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"NIH","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human iPSC-derived cardiac tissues","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"","sponsorNew":"NanoSurface Biomedical \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ NIH"}]

Find Clinical Drug Pipeline Developments & Deals by NanoSurface Biomedical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 03, 2020

                          Lead Product(s) : Human iPSC-derived cardiac tissues

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : NIH

                          Deal Size : $4.6 million

                          Deal Type : Funding

                          blank